Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;55(9):784-794.
doi: 10.1111/cea.70101. Epub 2025 Jun 27.

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study

Massimo Triggiani  1 , Jessica Hobart  2 , Iván Alvarez-Twose  3 , Cristina Bulai Livideanu  4 , Franziska Ruëff  5 , Stéphane Barete  6 , Patrizia Bonadonna  7 , Laurence Bouillet  8 , Nauman M Butt  9 , Mark Drummond  10 , Mar Guilarte  11 , Karin Hartmann  12   13   14 , Amélie Beaux  15 , Celeste C Finnerty  16 , Nicole Hegmann  17 , Patrizia Marcis  18 , Eugenia Ribada  19 , Waltraud Schinhofen  20 , Gabriela Coletti  21 , Andrew Dugdale  2 , Cristian Perez  22 , Dakota Powell  22 , Teresa Green  22 , Erin Sullivan  22 , Deepti H Radia  23 , Ruben Mesa  24
Affiliations

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study

Massimo Triggiani et al. Clin Exp Allergy. 2025 Sep.

Abstract

Background: Systemic mastocytosis (SM) is a clonal mast cell disease primarily driven by the KIT D816V mutation and often characterised by unpredictable and debilitating symptoms. The Perceptions Realities and Insights on Systemic Mastocytosis (PRISM) survey queried patient and provider perceptions of SM in Europe.

Methods: PRISM (funded by Blueprint Medicines Corporation) was composed of two independent surveys: a 119-item patient survey on diagnosis, symptom burden, quality of life (QoL) and work impact; and a 103-item healthcare provider (HCP) survey on approaches to SM diagnosis and management.

Results: Data were evaluated from 540 patient respondents from Italy (n = 136), France (n = 112), the UK (n = 101), Germany (n = 83), Spain (n = 64), Austria (n = 26) and Switzerland (n = 18). Patients reported a high symptom burden and reduced physical functioning and mental health due to SM, despite taking, on average, seven medications. A majority of patients reported that SM impacted their ability to work (58.9%). A total of 618 HCP responses were collected from Italy (n = 203), Germany (n = 123), the UK (n = 110), Austria (n = 63), France (n = 56), Switzerland (n = 44) and Spain (n = 19). Various HCP types reported treating patients with SM; the majority were haematologists/oncologists (n = 167) and general practitioners (n = 178). HCPs perceived that SM impacted their patients' QoL, with 54% reporting SM affected patients' lives 'quite a bit'. The most frequently reported treatment goals were improving QoL and survival.

Conclusions: PRISM is the largest international and first European survey to evaluate the burden of SM from both patient and HCP perspectives. Patients and HCPs perceived a high symptom burden, reduced QoL and reduced ability to work due to SM.

Keywords: cross‐sectional studies; disease burden; healthcare provider (HCP) perceptions; patient‐reported outcomes; systemic mastocytosis.

PubMed Disclaimer

References

    1. P. Bose and S. Verstovsek, “Avapritinib for Systemic Mastocytosis,” Expert Review of Hematology 14, no. 8 (2021): 687–696.
    1. A. Pardanani, “Systemic Mastocytosis in Adults: 2023 Update on Diagnosis, Risk Stratification and Management,” American Journal of Hematology 98, no. 7 (2023): 1097–1116.
    1. S. S. Cohen, S. Skovbo, H. Vestergaard, et al., “Epidemiology of Systemic Mastocytosis in Denmark,” British Journal of Haematology 166, no. 4 (2014): 521–528.
    1. J. Ungerstedt, C. Ljung, M. Klimkowska, and T. Gulen, “Clinical Outcomes of Adults With Systemic Mastocytosis: A 15‐Year Multidisciplinary Experience,” Cancers (Basel) 14, no. 16 (2022): 3942.
    1. K. H. Lim, A. Tefferi, T. L. Lasho, et al., “Systemic Mastocytosis in 342 Consecutive Adults: Survival Studies and Prognostic Factors,” Blood 113, no. 23 (2009): 5727–5736.

LinkOut - more resources